Arcutis Biotherapeutics, Inc.ARQTEarnings & Financial Report
Nasdaq
NextMar 31, 2026
ARQT Q3 2025 Key Financial Metrics
Revenue
$99.2M
Gross Profit
$90.5M
Operating Profit
$8.5M
Net Profit
$7.4M
Gross Margin
91.2%
Operating Margin
8.6%
Net Margin
7.5%
YoY Growth
121.7%
EPS
$0.06
Financial Flow
Arcutis Biotherapeutics, Inc. Q3 2025 Financial Summary
Arcutis Biotherapeutics, Inc. reported revenue of $99.2M for Q3 2025, with a net profit of $7.4M (7.5% margin). Cost of goods sold was $8.7M, operating expenses totaled $82.0M.
Key Financial Metrics
| Total Revenue | $99.2M |
|---|---|
| Net Profit | $7.4M |
| Gross Margin | 91.2% |
| Operating Margin | 8.6% |
| Report Period | Q3 2025 |
Arcutis Biotherapeutics, Inc. Annual Revenue by Year
Arcutis Biotherapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $196.5M).
| Year | Annual Revenue |
|---|---|
| 2024 | $196.5M |
| 2023 | $59.6M |
| 2022 | $3.7M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.5M | $49.6M | $30.9M | $44.8M | $71.4M | $65.8M | $81.5M | $99.2M |
| YoY Growth | 356.8% | 1682.4% | 494.6% | 17.4% | 427.6% | 32.8% | 164.1% | 121.7% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $341.4M | $478.5M | $444.8M | $437.4M | $348.9M | $344.1M | $352.4M | $371.0M |
| Liabilities | $252.7M | $253.6M | $258.3M | $280.7M | $191.3M | $201.4M | $213.5M | $212.9M |
| Equity | $88.7M | $224.9M | $186.4M | $156.6M | $157.5M | $142.7M | $139.0M | $158.1M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-56.2M | $-31.6M | $-45.1M | $-34.7M | $-748000 | $-30.4M | $324000 | $-1.8M |